Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease

Chronic Obstructive Pulmonary Disease (COPD) is the third commonest cause of death worldwide. Its natural course is a decline in lung function, punctuated by exacerbations, leading to premature death. COPD pathogenesis remains incompletely understood. The disease is widely accepted to result from an...

Full description

Bibliographic Details
Main Author: Mallia-Milanes, Brendan
Format: Thesis (University of Nottingham only)
Language:English
Published: 2015
Online Access:https://eprints.nottingham.ac.uk/74156/
_version_ 1848800845912604672
author Mallia-Milanes, Brendan
author_facet Mallia-Milanes, Brendan
author_sort Mallia-Milanes, Brendan
building Nottingham Research Data Repository
collection Online Access
description Chronic Obstructive Pulmonary Disease (COPD) is the third commonest cause of death worldwide. Its natural course is a decline in lung function, punctuated by exacerbations, leading to premature death. COPD pathogenesis remains incompletely understood. The disease is widely accepted to result from an excess protease over protective anti-protease activity, leading to extracellular matrix (ECM) damage in the lungs. However, this belief is oversimplified since both harmful pro-inflammatory and protective anti-inflammatory roles are now described for proteases in animal and cell culture models. Matrix Metalloproteinase (MMP)-12 was originally implicated in COPD by its degradation of elastin in the lung ECM. However, newer in vitro evidence reveals MMP-12 to target substrates outside the ECM. Given these newer findings it was hypothesized that MMP-12 cleaves non-ECM proteins in COPD which may contribute to the disease process. This hypothesis was addressed initially using a candidate-based approach, by testing osteopontin and tissue factor pathway inhibitor as potential MMP-12 substrates. However, these proved to be neutrophil elastase targets. Next, a novel proteomic technique called TAILS (Terminal Amine Isotopic Labelling of Substrates) was employed to identify potential MMP-12 substrates using a Mmpl2-/-smoking mouse model. This led to the discovery of new non-ECM MMP-12 substrates in the mouse model. Next, these findings were translated to human COPD sputum to identify potential MMP-12 targets in COPD, both at exacerbation and during stable disease. Similarly, within human COPD sputum non-ECM MMP-12 substrates were discovered, of particular interest, complement factor C3 and the anticoagulant anti-thrombin III, revealing ever new potential roles for MMP-12 in COPD.
first_indexed 2025-11-14T20:58:02Z
format Thesis (University of Nottingham only)
id nottingham-74156
institution University of Nottingham Malaysia Campus
institution_category Local University
language English
last_indexed 2025-11-14T20:58:02Z
publishDate 2015
recordtype eprints
repository_type Digital Repository
spelling nottingham-741562025-02-28T12:27:28Z https://eprints.nottingham.ac.uk/74156/ Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease Mallia-Milanes, Brendan Chronic Obstructive Pulmonary Disease (COPD) is the third commonest cause of death worldwide. Its natural course is a decline in lung function, punctuated by exacerbations, leading to premature death. COPD pathogenesis remains incompletely understood. The disease is widely accepted to result from an excess protease over protective anti-protease activity, leading to extracellular matrix (ECM) damage in the lungs. However, this belief is oversimplified since both harmful pro-inflammatory and protective anti-inflammatory roles are now described for proteases in animal and cell culture models. Matrix Metalloproteinase (MMP)-12 was originally implicated in COPD by its degradation of elastin in the lung ECM. However, newer in vitro evidence reveals MMP-12 to target substrates outside the ECM. Given these newer findings it was hypothesized that MMP-12 cleaves non-ECM proteins in COPD which may contribute to the disease process. This hypothesis was addressed initially using a candidate-based approach, by testing osteopontin and tissue factor pathway inhibitor as potential MMP-12 substrates. However, these proved to be neutrophil elastase targets. Next, a novel proteomic technique called TAILS (Terminal Amine Isotopic Labelling of Substrates) was employed to identify potential MMP-12 substrates using a Mmpl2-/-smoking mouse model. This led to the discovery of new non-ECM MMP-12 substrates in the mouse model. Next, these findings were translated to human COPD sputum to identify potential MMP-12 targets in COPD, both at exacerbation and during stable disease. Similarly, within human COPD sputum non-ECM MMP-12 substrates were discovered, of particular interest, complement factor C3 and the anticoagulant anti-thrombin III, revealing ever new potential roles for MMP-12 in COPD. 2015 Thesis (University of Nottingham only) NonPeerReviewed application/pdf en arr https://eprints.nottingham.ac.uk/74156/1/716487.pdf Mallia-Milanes, Brendan (2015) Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease. PhD thesis, University of Nottingham.
spellingShingle Mallia-Milanes, Brendan
Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease
title Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease
title_full Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease
title_fullStr Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease
title_full_unstemmed Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease
title_short Identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease
title_sort identifying matrix metalloproteinase-12 substrates as therapeutic targets in chronic obstructive pulmonary disease
url https://eprints.nottingham.ac.uk/74156/